Completed PHASE3 INTERVENTIONAL 2-arm NCT00644007

Phase III Study to Assess the Efficacy and Safety of SK3530 in Patients With Erectile Dysfunction and Hypertension

A Double Blind, Randomized, Placebo-controlled, Parallel Group, Multi-center, Phase III Study to Assess the Efficacy and Safety of SK3530 in Patients With Erectile Dysfunction Taking Antihypertensive Medication

Sponsor: SK Chemicals Co., Ltd.

Conditions Erectile Dysfunction

Interventions Placebo SK3530

Updated 7 times since 2017 Last updated: Apr 16, 2013 Started: Dec 31, 2007 Primary completion: Sep 30, 2008 Completion: Dec 31, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Erectile Dysfunction and is currently completed. SK Chemicals Co., Ltd. leads this study, which shows 7 recorded versions since 2007 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Feb 2019 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Jun 2018 — Feb 2019 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Dec 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

SK Chemicals Co., Ltd.

Data source: SK Chemicals Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Seoul, South Korea